Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse.
Location: United States, Massachusetts, Woburn
Total raised: $85M
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Omega Fund... | omegafunds... |
| - | Forbion | forbion.co... |
| - | Atlas Vent... | atlasventu... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.09.2017 | Series B | $55M | Foresite C... |
| 24.09.2015 | Series A | $30M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 20.04.2024 | The Melanoma Research Foundation to host the New England Mil... | New England Miles for Melanoma The Melanoma Research Foundation (MRF) is thrilled to announce one of... | prweb.com/... |
| 06.03.2024 | Replimune to Present at the American Association for Cancer ... | - | globenewsw... |
| 05.03.2024 | Replimune to Present at Three Upcoming Investor Conferences | - | globenewsw... |
| 03.06.2023 | Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed ... | /EIN News/ -- Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined wi... | einpresswi... |
| 07.10.2022 | Replimune Secures $200 Million in Non-Dilutive Debt Financin... | WOBURN, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical st... | globenewsw... |
| 01.10.2021 | Replimune : Announces Presentations at the 2021 Society for ... | WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnolo... | marketscre... |
| 27.08.2021 | AstraZeneca promotes oncology exec to CMO; Pfizer re... | Cristian Massacesi The biggest bright spot for AstraZeneca over the last few years has been its... | endpts.com... |
| 07.08.2020 | REPLIMUNE GROUP, INC. Replimune Reports Fiscal First Quarte... | Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of im... | marketscre... |
| 13.09.2018 | BI Joins Pharma Frenzy For Cancer-Killing Viruses With $244M... | Boehringer Ingelheim is the latest company to acquire technology to transform viruses into cancer...... | forbes.com... |
| 10.07.2018 | Antibody maker Vaccinex files $46M IPO touting I/O com... | → After spending over a decade building out a pipeline of antibody drugs to treat cancer, neu... | endpts.com... |
Show more